7689-62-5

Usage

Uses

Used in Organic Synthesis:
2-Chloro-1,5-naphthyridine is used as a key intermediate in the synthesis of various organic compounds due to its reactivity and ability to participate in a variety of chemical reactions.
Used in Pharmaceutical Industry:
2-Chloro-1,5-naphthyridine is used as a building block for the development of pharmaceuticals, contributing to the creation of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
2-Chloro-1,5-naphthyridine is also utilized as a building block in the development of agrochemicals, playing a role in the production of compounds with agricultural applications.
It is important to handle 2-Chloro-1,5-naphthyridine with care and follow proper safety protocols when working with it in a laboratory setting to ensure the safety of both the personnel and the environment.

InChI:InChI=1/C8H5ClN2/c9-8-4-3-6-7(11-8)2-1-5-10-6/h1-5H

Upstream product

• 10261-82-2 1,5-naphthyridin-2(1H)-one 
• 27305-48-2 1,5-naphthyridine N-⁽¹⁾-oxide 
• 10261-82-2 2-Hydroxy-1,5-naphthyridin 
• 6298-19-7 2-chloro-3-aminopyridine 
• 39856-58-1 3-amino-2-bromopyridine 
• 1452561-63-5 (E)-methyl 3-(3-aminopyridin-2-yl)acrylate 
• 254-79-5 1,5-naphthyridine 
• 462-08-8 pyridin-3-ylamine 
• 10026-13-8 phosphorus pentachloride 
• 10025-87-3 trichlorophosphate 

Downstream Products

• 10261-82-2 1,5-naphthyridin-2(1H)-one 
• 1201842-49-0 N-(2-chloro-5-(1,5-naphthyridin-2-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 
• 1309774-03-5 7-bromo-2-chloro-1,5-naphthyridine 
• 1422123-35-0 C₂₁H₂₂N₄O₃ 
• 1422123-99-6 C₂₂H₂₂N₆O 
• 1422124-32-0 C₂₁H₂₀N₆O 
• 1422124-72-8 C₂₁H₂₁N₅O₂ 
• 1422125-49-2 C₂₄H₂₅N₇O₄S 
• 1422125-93-6 C₂₂H₂₃N₇O 
• 1422125-94-7 N-((7-(1-methyl-1H-pyrazol-4-yl)-1,5-naphthyridin-2-yl)carbamothioyl)benzamide 

Relevant academic research and scientific papers

INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS

Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF

A compound represented by Formula [1] (in the formula, Z1 represents N, CH, or the like; X1 represents NH or the like; R1 represents a heteroaryl group or the like; each of R2, R3, and R4 represents a hydrogen atom, a halogen atom, an alkoxy group, or the like; and R5 represents a heteroaryl group or the like) or salt thereof.

1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF

A 1,5-naphthyridine derivative represented by Formula [1] (in which R1, R2, R3, R4 and R5 represent a hydrogen atom, -L-Z (in which Z represents a non-aromatic heterocyclic group or the like; and L re

HETEROBICYCLIC COMPOUNDS

Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.

Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: Discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives

The phosphoinositide 3-kinase (PI3K) family catalyzes the ATP-dependent phosphorylation of the 3′-hydroxyl group of phosphatidylinositols and plays an important role in cell growth and survival. There is abundant evidence demonstrating that PI3K signaling is dysregulated in many human cancers, suggesting that therapeutics targeting the PI3K pathway may have utility for the treatment of cancer. Our efforts to identify potent, efficacious, and orally available PI3K/mammalian target of rapamycin (mTOR) dual inhibitors resulted in the discovery of a series of substituted quinolines and quinoxalines derivatives. In this report, we describe the structure-activity relationships, selectivity, and pharmacokinetic data of this series and illustrate the in vivo pharmacodynamic and efficacy data for a representative compound.

INHIBITORS OF PI3 KINASE

The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein Q, X1, X2, R1 and Z are as defined herein.